$350 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 90 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 62.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXDX | Sell | Prometheus Bioscience, Inc.put | $18,964,000 | +57.0% | 172,400 | -15.8% | 5.42% | +32.8% |
| MDGL | New | Madrigal Pharmaceuticals Incequities | $14,482,895 | – | 49,898 | +100.0% | 4.14% | – |
| BLU | Buy | Bellus Health Incequities | $14,034,581 | -19.7% | 1,707,370 | +3.1% | 4.02% | -32.1% |
| PSTX | Sell | Poseida Therapeutics Incequities | $11,819,000 | +31.1% | 2,230,000 | -12.7% | 3.38% | +10.9% |
| VRAY | Buy | Viewray Incequities | $10,776,013 | +27.4% | 2,405,360 | +3.5% | 3.08% | +7.7% |
| XENE | Buy | Xenon Pharmaceuticals Incequities | $10,001,617 | +12.6% | 253,655 | +3.1% | 2.86% | -4.8% |
| AKRO | Sell | Akero Therapeutics Incequities | $9,431,080 | -7.7% | 172,100 | -42.6% | 2.70% | -21.9% |
| AVXL | Buy | Anavex Life Science Corpput | $9,331,302 | -4.1% | 1,007,700 | +6.9% | 2.67% | -18.8% |
| IMVT | Buy | Immunovant Incequities | $9,223,149 | +451.0% | 519,614 | +73.2% | 2.64% | +366.3% |
| Buy | Nuvalent Incequities | $9,022,238 | +1019.4% | 302,963 | +631.1% | 2.58% | +845.4% | |
| ALNY | Buy | Alnylam Pharmaceuticals Incequities | $8,947,998 | +37.4% | 37,652 | +15.7% | 2.56% | +16.2% |
| MORF | Buy | Morphic Holding Incequities | $8,948,811 | -2.5% | 334,535 | +3.1% | 2.56% | -17.6% |
| MDGL | New | Madrigal Parmaceuticals, Inc.put | $8,707,500 | – | 30,000 | +100.0% | 2.49% | – |
| AKRO | New | Akero Therapeutics Inccall | $8,220,000 | – | 150,000 | +100.0% | 2.35% | – |
| AKRO | New | Akero Therapeutics Incput | $8,220,000 | – | 150,000 | +100.0% | 2.35% | – |
| ITCI | Buy | Intra-Cellular Therapies Incequities | $7,428,169 | +17.3% | 140,366 | +3.1% | 2.12% | -0.8% |
| ORIC | Buy | Oric Pharmaceuticals Incequities | $7,281,783 | +88.2% | 1,236,296 | +2.3% | 2.08% | +59.1% |
| TERN | Buy | Terns Pharmaceuticals Incequities | $7,126,000 | +8283.5% | 700,000 | +4736.6% | 2.04% | +6931.0% |
| MRSN | Buy | Mersana Therapeutics Incequities | $6,681,467 | -0.6% | 1,140,182 | +14.7% | 1.91% | -15.9% |
| BIIB | New | Biogen Idec Incequities | $6,085,317 | – | 21,975 | +100.0% | 1.74% | – |
| CERS | Buy | Cerus Corpequities | $5,964,151 | +2.5% | 1,634,014 | +1.1% | 1.71% | -13.3% |
| CVRX | Buy | Cvrx Incequities | $5,772,616 | +100.9% | 314,584 | +2.2% | 1.65% | +69.9% |
| ACRS | Sell | Aclaris Therapeutics Incequities | $5,547,040 | -35.2% | 352,193 | -35.2% | 1.59% | -45.2% |
| RXDX | New | Prometheus Biosciences Incequities | $5,500,000 | – | 50,000 | +100.0% | 1.57% | – |
| New | Cincor Pharma Incequities | $4,859,245 | – | 395,382 | +100.0% | 1.39% | – | |
| New | GlaxoSmithKline PLCequities | $4,785,295 | – | 136,178 | +100.0% | 1.37% | – | |
| VCYT | Sell | Veracyte Incequities | $4,746,000 | -57.1% | 200,000 | -70.0% | 1.36% | -63.7% |
| KRYS | Buy | Krystal Biotech Incequities | $4,637,143 | +17.5% | 58,535 | +3.3% | 1.33% | -0.6% |
| BCAB | Buy | Bioatla Incequities | $4,511,719 | +192.4% | 546,875 | +172.9% | 1.29% | +147.3% |
| UTHR | Buy | United Therapeutics Corpequities | $4,462,788 | +99.2% | 16,048 | +50.0% | 1.28% | +68.5% |
| GILD | New | Gilead Sciences Incequities | $4,460,938 | – | 51,962 | +100.0% | 1.28% | – |
| PRTA | Sell | Prothena Corporation PLCequities | $4,320,287 | -35.2% | 71,706 | -34.8% | 1.24% | -45.2% |
| MRUS | Sell | Merus NVequities | $4,249,671 | -28.1% | 274,704 | -6.9% | 1.22% | -39.2% |
| PLRX | Buy | Pliant Therapeutics Incequities | $4,204,333 | -4.1% | 217,503 | +3.7% | 1.20% | -18.9% |
| MGNX | Buy | MacroGenics Incequities | $4,109,707 | +1087.8% | 612,475 | +512.5% | 1.18% | +905.1% |
| ALLK | Buy | Allakos Incequities | $4,047,502 | +65.3% | 480,701 | +20.2% | 1.16% | +39.9% |
| PCVX | New | Vaxcyte Incequities | $3,986,323 | – | 83,135 | +100.0% | 1.14% | – |
| IMTX | Buy | Immatics Nvequities | $3,830,553 | +133.7% | 439,788 | +168.3% | 1.10% | +97.8% |
| VRTX | Buy | Vertex Pharmaceuticals Incequities | $3,287,472 | +2.3% | 11,384 | +2.5% | 0.94% | -13.5% |
| BCRX | Buy | BioCryst Pharmaceuticals Incequities | $3,124,546 | +32.9% | 272,173 | +45.9% | 0.89% | +12.5% |
| PNT | Buy | Point Biopharma Global Incequities | $2,921,919 | +26.0% | 400,812 | +33.6% | 0.84% | +6.6% |
| RNA | New | Avidity Biosciences Incequities | $2,840,320 | – | 128,000 | +100.0% | 0.81% | – |
| ASND | Buy | Ascendis Pharma A/Sequities | $2,827,432 | +448.0% | 23,151 | +363.0% | 0.81% | +362.3% |
| CRNX | Buy | Crinetics Pharmaceuticals Incequities | $2,795,270 | -4.5% | 152,747 | +2.5% | 0.80% | -19.2% |
| PHR | Buy | Phreesia Incequities | $2,763,220 | +30.2% | 85,390 | +2.5% | 0.79% | +10.2% |
| ALT | New | Altimmune, Inc.call | $2,632,000 | – | 160,000 | +100.0% | 0.75% | – |
| HZNP | Buy | Horizon Therapeutics Plcequities | $2,623,545 | +318.4% | 23,054 | +127.6% | 0.75% | +254.2% |
| INSM | Sell | Insmed Incequities | $2,486,811 | -48.5% | 124,465 | -44.4% | 0.71% | -56.4% |
| CLDX | Buy | Celldex Therapeutics Incequities | $2,437,934 | +62.7% | 54,699 | +2.7% | 0.70% | +37.5% |
| CGEM | Buy | Cullinan Oncology Incequities | $2,420,339 | -15.9% | 229,416 | +2.2% | 0.69% | -29.0% |
| MCRB | Buy | Seres Therapeutics Incequities | $2,096,763 | -10.9% | 374,422 | +2.2% | 0.60% | -24.6% |
| COGT | Sell | Cogent Biosciences Incequities | $2,069,240 | -77.1% | 179,000 | -70.5% | 0.59% | -80.7% |
| IMGN | Sell | ImmunoGen Incequities | $2,020,054 | -3.7% | 407,269 | -7.2% | 0.58% | -18.5% |
| SDGR | New | Schrodinger Incequities | $2,018,520 | – | 108,000 | +100.0% | 0.58% | – |
| ISEE | Sell | IVERIC bio Incequities | $1,889,283 | -40.6% | 88,243 | -50.2% | 0.54% | -49.8% |
| ABOS | Sell | Acumen Pharmaceuticals Incequities | $1,593,621 | -62.2% | 295,115 | -29.7% | 0.46% | -68.0% |
| LVTX | Sell | LAVA Therapeutics NVequities | $1,532,167 | -45.1% | 437,762 | -28.3% | 0.44% | -53.6% |
| CTIC | Sell | CTI BioPharma Corpequities | $1,528,710 | -73.3% | 254,361 | -74.1% | 0.44% | -77.4% |
| Buy | Eliem Therapeutics Incequities | $1,501,771 | +15.6% | 409,202 | +1.8% | 0.43% | -2.1% | |
| TRVI | Sell | Trevi Therapeutics Incequities | $1,481,528 | +2.5% | 767,631 | -18.3% | 0.42% | -13.3% |
| SGEN | Buy | Seagen Incequities | $1,415,666 | -2.6% | 11,016 | +3.7% | 0.40% | -17.7% |
| AMYT | Buy | Amryt Pharma PLCequities | $1,408,864 | +8.1% | 192,995 | +2.5% | 0.40% | -8.6% |
| CMPX | Buy | Compass Therapeutics Inc.equities | $1,349,584 | +125.7% | 268,307 | +2.4% | 0.39% | +91.1% |
| New | Astria Therapeutics Incequities | $1,209,128 | – | 81,204 | +100.0% | 0.35% | – | |
| IMGN | New | ImmunoGen, Inc.call | $1,150,720 | – | 232,000 | +100.0% | 0.33% | – |
| NTLA | Buy | Intellia Therapeutics Incequities | $1,143,345 | -36.2% | 32,770 | +2.4% | 0.33% | -46.0% |
| PHVS | New | Pharvaris NVequities | $1,125,000 | – | 100,000 | +100.0% | 0.32% | – |
| AVTE | New | Aerovate Therapeutics Incequities | $1,081,346 | – | 36,906 | +100.0% | 0.31% | – |
| AVXL | Buy | Anavex Life Science Corpcall | $950,076 | -7.9% | 102,600 | +2.6% | 0.27% | -22.1% |
| VERU | Sell | Veru Inc.put | $924,000 | -85.4% | 175,000 | -68.2% | 0.26% | -87.7% |
| CUE | New | Cue Biopharma Incequities | $872,892 | – | 306,278 | +100.0% | 0.25% | – |
| ALT | Sell | Altimmune Incequities | $831,482 | -35.2% | 50,546 | -49.7% | 0.24% | -45.2% |
| CYTK | New | Cytokinetics Incequities | $801,850 | – | 17,500 | +100.0% | 0.23% | – |
| AXSM | New | Axsome Therapeutics Incequities | $771,300 | – | 10,000 | +100.0% | 0.22% | – |
| STXS | Buy | Stereotaxis Incequities | $734,695 | +17.9% | 354,925 | +2.5% | 0.21% | -0.5% |
| CDXS | Sell | Codexis Incequities | $674,474 | -23.4% | 144,737 | -0.5% | 0.19% | -35.2% |
| DSGN | New | Design Therapeutics Incequities | $585,077 | – | 57,025 | +100.0% | 0.17% | – |
| IMUX | New | Immunic Incequities | $490,918 | – | 350,656 | +100.0% | 0.14% | – |
| CGEN | New | Compugen Ltdequities | $477,689 | – | 667,443 | +100.0% | 0.14% | – |
| MGTX | Buy | Meiragtx Holdings Plcequities | $369,501 | -20.5% | 56,672 | +2.4% | 0.11% | -32.5% |
| WVE | New | WAVE Life Sciences Ltdequities | $350,000 | – | 50,000 | +100.0% | 0.10% | – |
| New | Braze Incequities | $272,800 | – | 10,000 | +100.0% | 0.08% | – | |
| PRAX | Sell | Praxis Precision Medicines Incequities | $234,213 | +3.2% | 98,409 | -1.6% | 0.07% | -13.0% |
| QURE | New | Uniqure NVequities | $226,700 | – | 10,000 | +100.0% | 0.06% | – |
| GOSS | New | Gossamer Bio Incequities | $217,000 | – | 100,000 | +100.0% | 0.06% | – |
| EVGN | Sell | Evogene Ltdequities | $105,253 | -24.3% | 150,361 | -10.2% | 0.03% | -36.2% |
| VRDN | New | Viridian Therapeutics Incequities | $87,630 | – | 3,000 | +100.0% | 0.02% | – |
| New | Eloxx Pharmaceuticals Incequities | $48,914 | – | 26,876 | +100.0% | 0.01% | – | |
| New | Fresh Tracks Therapeutics Incequities | $15,000 | – | 10,000 | +100.0% | 0.00% | – | |
| MSACW | Medicus Sciences Acquisition Corpwarrants | $4,499 | +349.9% | 49,990 | 0.0% | 0.00% | – | |
| Exit | RENOVACOR INC*w exp 99/99/999 | $0 | – | -104,828 | -100.0% | -0.00% | – | |
| PYPD | Exit | POLYPID LTDput | $0 | – | -50,000 | -100.0% | -0.02% | – |
| ELOX | Exit | ELOXX PHARMACEUTICALS INC | $0 | – | -1,098,469 | -100.0% | -0.06% | – |
| NCNA | Exit | NUCANA PLCsponsored adr | $0 | – | -269,682 | -100.0% | -0.10% | – |
| PRTA | Exit | PROTHENA CORP PLCput | $0 | – | -5,000 | -100.0% | -0.10% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -10,220 | -100.0% | -0.24% | – |
| EYPT | Exit | EYEPOINT PHARMACEUTICALS INC | $0 | – | -108,285 | -100.0% | -0.29% | – |
| NGM | Exit | NGM BIOPHARMACEUTICALS INC | $0 | – | -94,517 | -100.0% | -0.42% | – |
| ETNB | Exit | 89BIO INC | $0 | – | -250,000 | -100.0% | -0.49% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -40,741 | -100.0% | -0.61% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC NE | $0 | – | -314,095 | -100.0% | -0.71% | – |
| KRTX | Exit | KARUNA THERAPEUTICS INC | $0 | – | -10,323 | -100.0% | -0.78% | – |
| RGNX | Exit | REGENXBIO INC | $0 | – | -110,085 | -100.0% | -0.98% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INCcall | $0 | – | -42,500 | -100.0% | -1.00% | – |
| NKTX | Exit | NKARTA INC | $0 | – | -362,377 | -100.0% | -1.61% | – |
| CLNN | Exit | CLENE INCput | $0 | – | -1,734,800 | -100.0% | -1.64% | – |
| APEN | Exit | APOLLO ENDOSURGERY INC | $0 | – | -1,136,206 | -100.0% | -2.12% | – |
| ISEE | Exit | IVERIC BIO INCput | $0 | – | -443,100 | -100.0% | -2.69% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INCput | $0 | – | -393,000 | -100.0% | -4.92% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- SILVERARC CAPITAL, LLC #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.